Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    Uncategorized Posts

    Chondrosarcoma Foundation Efforts to Promote Genomic Sequencing Tests

    April 22nd, 2024

    Genomic sequencing is a promising tool for expanding the treatment options for chondrosarcoma patients. Genomic sequencing technologies are capable of characterizing known and novel clinically relevant biomarkers, like IDH1/2, and is becoming a…

    Read Article

    Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options

    April 4th, 2024

    Abstract
    This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS), including grade 2–3 conventional, dedifferentiated, and mesenchymal…

    Read Article

    Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report

    March 26th, 2024

    Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report Veronika Blum, 1 , † Vanghelita Andrei, 2 , † Baptiste Ameline, 2 Silvia Hofer, 3 Bruno Fuchs, 1 Klaus Strobel, 1 Anna Allemann, 1 Beata Bode, 4…

    Read Article

    Chondrosarcoma Foundation Introduces a new Patient Guide: Making the Decision to enroll in a Clinical Trial.

    March 3rd, 2024

    Typically after surgery, it is important to know what post-surgical options are available. Making the decision to enroll in a clinical trial is one of those options and maybe one of the most important decisions chondrosarcoma patients and their…

    Read Article

    Chondrosarcoma Foundation Efforts to Promote Genomic Sequencing

    February 25th, 2024

    Genomic sequencing is a promising tool for expanding the treatment options for chondrosarcoma patients. Genomic sequencing technologies are capable of characterizing known and novel clinically relevant biomarkers, like IDH1/2, and is becoming a…

    Read Article

    Dan Hurley, M.D. Endowment Fund for Insurance Authorizations

    February 23rd, 2024

    Daniel Brian Hurley, M.D. passed away August 3, 2023, from dedifferentiated chondrosarcoma at age 50 surrounded by his loved ones. His wife Traci and their three kids Rachel, Sam, and Sarah were the light of his life. His family, including his…

    Read Article

    Call for Action

    February 19th, 2024

    Be Part of the First full Analysis of the Chondrosarcoma Patient Registry https://chondrosarcoma.iamrare.org

    It is not too late to sign up to participate in the Chondrosarcoma Patient Registry. The Chondrosarcoma Foundation has been preparing to…

    Read Article

    Thank You for Supporting Chondrosarcoma Awareness Day

    February 8th, 2024

    Thank You!!!!

    To Everyone that participated in Chondrosarcoma Awareness Day. It is wonderful to see people from all over the globe come together to honor our CS survivors and those who lost their battle to this terrible bone cancer. And it is great…

    Read Article

    Final Tribute and Introduction of the Daniel B. Hurley, M.D. Endowment Fund

    February 5th, 2024

    Tomorrow, February 6 is Chondrsarcoma Awareness Day.

    Join the Fight

    Wear something Yellow.

    Take a picture (family, friends, work colleagues) and post it to #cswecare #chondrosarcoma #chondrosarcomafoundation

    Sign our Petition to support more…

    Read Article

    Tuesday February 6 is Chondrosarcoma Awareness Day.

    February 2nd, 2024

    This coming Tuesday, February 6 is Chondrsarcoma Awareness Day.

    Join the Fight

    Wear something Yellow.

    Take a picture (family, friends, work colleagues) and post it to #cswecare #chondrosarcoma #chondrosarcomafoundation

    Sign our Petition to…

    Read Article
    Skip to content